ClinicalTrials.gg
CompletedNCT04732117Updated Apr 9, 2026Results posted

Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

A Phase 3 interventional study of Secukinumab and Placebo in Non-radiographic Axial Spondyloarthritis, sponsored by Novartis Pharmaceuticals. Completed at 29 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China — 6 open to participants now, 6 under way, 3 of them phase 3. Non-Radiographic Axial Spondyloarthritis · China.

Enrollment
8th of 10
137 · median 227
Started
2021
with 1 other
Phase 3
6 of 11
2 open now
Registered
3rd of 11
by date
Lead sponsor
1 of 11
Novartis Pharmaceuticals

Among the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 3rd registered.

Non-Radiographic Axial Spondyloarthritis

33 studies on the registry are indexed under Non-Radiographic Axial Spondyloarthritis; 12 are open to participants now.

Browse Non-Radiographic Axial Spondyloarthritis studies →

Open to participants now

6 of the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Non-Radiographic Axial Spondyloarthritis studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy, safety, and tolerability of secukinumab in Chinese patients with active non-radiographic axial spondyloarthritis (nr-axSpA).

Read the detailed description

This was a randomized, double-blind, placebo-controlled study. Approximately 134 participants were planned to be randomized in a 1:1 ratio to receive secukinumab 150 mg subcutaneously (s.c.) or placebo.

The double-blind treatment period lasted for 16 weeks. At the end of this period, all participants, including those who initially received placebo, switched to open-label treatment with secukinumab 150 mg s.c.

The first dose of open-label treatment was administered at the Week 16 visit, after completing all necessary assessments for that visit. However, the participants and investigators remained blinded to the original treatment assignment. At Week 24, participants who did not respond to the treatment (defined as not achieving Ankylosing SpondyloArthritis International Society 20 [ASAS20] response) were given a higher dose of secukinumab (300 mg s.c.), while responders continued with the 150 mg s.c. dose. The study treatment continued until Week 48. Four weeks after the last study treatment administration, an end-of-treatment visit was conducted at Week 52.

Additionally, a post-treatment safety follow-up visit was performed 12 weeks after the last study treatment administration for all participants, whether they completed the entire study as planned or exited early.

03

Conditions studied

  • Non-radiographic Axial Spondyloarthritis

Keywords

  • non-radiographic spondyloarthritis
  • chronic inflammatory disease
  • inflammatory back pain,
  • secukinumab
  • AIN457
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-nursing female patients at least 18 years of age
  • Diagnosis of axial spondyloarthritis according to Ankylosing SpondyloArthritis International Society (ASAS) axial spondyloarthritis criteria
  • Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)
  • Active axial spondyloarthritis as assessed by total Bath Ankylosing Spondylitis Disease Activity Index >=4 cm
  • Spinal pain as measured by Bath Ankylosing Spondylitis Disease Activity Index question #2 ≥ 4 cm (0-10 cm) at baseline
  • Total back pain as measured by Visual Analogue scale ≥ 40 mm (0-100 mm) at baseline
  • Patients should have been on at least 2 different non-steroidal anti-inflammatory drugs with an inadequate response
  • Patients who have been on a TNFα inhibitor (not more than one) must have experienced an inadequate response

Exclusion criteria

Exclusion Criteria:

  • Patients with radiographic evidence for sacroiliitis, grade ≥ 2 bilaterally or grade ≥ 3 unilaterally
  • Inability or unwillingness to undergo MRI
  • Chest X-ray or MRI with evidence of ongoing infectious or malignant process
  • Patients taking high potency opioid analgesics
  • Previous exposure to secukinumab or any other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor
  • Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Participants received secukinumab 150 mg in a pre-filled syringe (PFS). Treatment was double-blinded until Week 12. From Week 16, participants continued with an open-label treatment of secukinumab 150 mg. At Week 24, non-responders (not achieving ASAS20) were escalated to secukinumab 300 mg, while responders continued with secukinumab 150 mg.

    Drug: Secukinumab

  • Placebo comparator
    Placebo

    Participants initially received a placebo in a pre-filled syringe (PFS) in a double-blinded manner until Week 12. At Week 16, they switched to an open-label treatment of secukinumab 150 mg. At Week 24, non-responders (not achieving ASAS20) were escalated to secukinumab 300 mg, while responders continued with secukinumab 150 mg.

    Drug: Placebo

Interventions

  • Secukinumab 150 mg s.c. using a PFS at Baseline, Weeks 1, 2, and 3, followed by administration every 4 weeks from Week 4 until Week 12. At Week 16, all participants continued or switched to receiving secukinumab 150 mg s.c. every 4 weeks, using a PFS. This treatment regimen continued from Week 16 through Week 48. For participants who did not respond to the secukinumab 150 mg dose during the open-label period, the dose was increased to 300 mg s.c., using two PFS, also administered every 4 weeks.

    Also known as: AIN457

  • DrugPlacebo

    Placebo s.c. using a PFS at baseline, Weeks 1, 2 and 3, followed by administration every 4 weeks from Week 4 until Week 12.

06

What researchers measure

Primary outcomes

  1. Assessment of SpondyloArthritis International Society 40 (ASAS40) Response Rate in TNF-alpha-inhibitor-naive Participants at Week 16

    ASAS40 response was defined as relative improvement of at least 40% and absolute improvement of at least 2 units on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening at all in the remaining domain. The 4 main domains of the ASAS are: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of TNF-alpha-inhibitor-naïve participants who achieved ASAS40 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders

    Time frame: Baseline, Week 16

Secondary outcomes

  1. ASAS40 Response Rate in All Participants at Week 16

    ASAS40 response was defined as relative improvement of at least 40% and absolute improvement of at least 2 units on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening at all in the remaining domain. The 4 main domains of the ASAS are: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of participants who achieved ASAS40 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders

    Time frame: Baseline, Week 16

  2. ASAS 5/6 Response Rate at Week 16.

    The ASAS 5/6 response was defined as an improvement of ≥20% in at least five of all six domains of the ASAS: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]); 5) spinal mobility represented by the BAS Disease Metrology Index (BASDMI) (scale ranged from 0 \[no limitation of movement\] to 10 \[very severe limitation of movement\]; and 6) C-reactive protein (acute phase reactant). The percentage of participants who achieved ASAS 5/6 response at Week 16 was assessed using a logistic regression model. Missing responses were imputed as non-responders. Discontinued participants were considered non-responders

    Time frame: Baseline, Week 16

  3. Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 16

    The BASDAI consisted of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which was used to answer 6 questions pertaining to the 5 major symptoms of AS: 1. Fatigue; 2. Spinal pain; 3. Joint pain / swelling; 4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments); 5. Morning stiffness duration; 6. Morning stiffness severity. BASDAI score was calculated as the mean of the questions 5 and 6. The resulting 0 to 10 score was added to the scores from questions 1-4. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score, where higher score indicated high disease activity. The change from baseline in BASDAI scores at Week 16 was assessed using Mixed-effects model repeated measures (MMRM). A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 16

  4. BASDAI 50 Rate at Week 16

    The BASDAI consisted of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which was used to answer 6 questions pertaining to the 5 major symptoms of AS: 1. Fatigue; 2. Spinal pain; 3. Joint pain / swelling; 4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments); 5. Morning stiffness duration; 6. Morning stiffness severity. BASDAI score was calculated as the mean of the questions 5 and 6. The resulting 0 to 10 score was added to the scores from questions 1-4. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score, where higher score indicated high disease activity. BASDAI 50 was defined as an improvement of at least 50% in the BASDAI total score compared to baseline. The percentage of participants achieving BASDAI 50 at Week 16 was assessed using a logistic regression model. Discontinued participants and with missing responses were considered non-responders

    Time frame: Baseline, Week 16

  5. Change From Baseline of High Sensitivity C-Reactive Protein (hsCRP) at Week 16

    hsCRP was measured as a marker of inflammation from blood samples. The change from baseline in hsCRP at Week 16 was assessed using MMRM. It was expressed as a ratio of Week 16 to baseline values. Ratios less than 1.0 at Week 16 represented reduced hsCRP.

    Time frame: Baseline, Week 16

  6. Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16

    The BASFI is a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The questions were chosen on the basis of predominant input from subjects with AS. The first eight questions consider activities related to functional anatomy. The final two questions assess the subjects' ability to cope with everyday life. A 0-10 scale (captured as a continuous VAS) is used to answer the questions. The BASFI score is the mean of the ten scales - a value between 0 and 10, with higher scores indicating a higher degree of functional limitation in patients. The change from baseline in BASFI at Week 16 was assessed. A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 16

  7. Change From Baseline in Sacroiliac Joint (SIJ) Edema Score on Magentic Resonance Imaging (MRI) at Week 16

    The MRI assessment of the total edema score of the Sacroiliac Joint (SIJ) measured the degree of edema or fluid accumulation in the joint. The score ranged from 0 to 24, with higher scores indicating more severe inflammation. The change from baseline in inflammation, as measured by the SI joint total edema score at Week 16, was evaluated using an ANCOVA model. Any missing data was imputed using multiple imputation prior to running the ANCOVA analysis.

    Time frame: Baseline, Week 16

  8. ASAS20 Response Rate at Week 16

    ASAS20 response was defined as relative improvement of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening of ≥20% and ≥1 unit at all in the remaining domain. The 4 main domains of ASAS are 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]) The percentage of participants who achieved ASAS20 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders

    Time frame: Baseline, Week 16

  9. Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS) at Week 16

    SF-36 was an instrument used to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consisted of eight subscales (domains) that could be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Each domain score ranged from 0 to 100, with higher scores indicating a higher level of functioning. The Physical Component Summary (PCS) was an overall summary score calculated from the 8 domains. It was a norm-based score with a mean of 50 and a standard deviation of 10. Higher scores indicated a higher level of functioning. The change from baseline in PCS at Week 16 was evaluated using MMRM. A positive change from baseline indicated an improvement.

    Time frame: Baseline, Week 16

  10. Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16

    The ASQoL was a self-administered questionnaire designed to assess health-related quality of life (HRQoL) in participants with ankylosing spondylitis. The ASQoL contained 18 items with a dichotomous yes/no response option. A single point was assigned for each "yes" response and no points for each "no" response resulting in overall scores that ranged from 0 (least severity) to 18 (highest severity). As such, a lower score indicated a better quality of life. Items included an assessment of mobility/energy, self-care, and mood/emotion. The change from baseline in ASQoL at Week 16 was assessed using MMRM. A negative change from baseline indicated an improvement.

    Time frame: Baseline, Week 16

  11. ASAS Partial Remission Rate at Week 16

    The ASAS partial remission criteria were defined as a value not above 2 units (on a scale of 10) in each of the 4 main ASAS domains: 1. Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2. Back Pain (assessed on a scale of 0 \[no pain\] to 10 \[severe pain\]); 3. Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4. Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of participants who achieved ASAS partial remission response at Week 16 was assessed using a logistic regression model. Missing responses were imputed as non-responders. Discontinued participants were considered non-responders.

    Time frame: Baseline, Week 16

07

Results

Posted Jan 30, 2026

Participant flow

Double-Blind period (up to Week 16)
Participant flow — Double-Blind period (up to Week 16)
MilestoneSecukinumabPlacebo
Started6869
Completed6768
Not completed11
Withdrew: Lost to follow-up10
Withdrew: Subject decision01
Open-label period
Participant flow — Open-label period
MilestoneSecukinumabPlacebo
Started6768
Escalated to secukinumab 300 mg1217
Completed6465
Not completed33
Withdrew: Subject discontinuation33

Outcome measures

PrimaryAssessment of SpondyloArthritis International Society 40 (ASAS40) Response Rate in TNF-alpha-inhibitor-naive Participants at Week 16

ASAS40 response was defined as relative improvement of at least 40% and absolute improvement of at least 2 units on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening at all in the remaining domain. The 4 main domains of the ASAS are: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of TNF-alpha-inhibitor-naïve participants who achieved ASAS40 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of participants
Assessment of SpondyloArthritis International Society 40 (ASAS40) Response Rate in TNF-alpha-inhibitor-naive Participants at Week 16
Percentage of participantsSecukinumabPlacebo
Assessment of SpondyloArthritis International Society 40 (ASAS40) Response Rate in TNF-alpha-inhibitor-naive Participants at Week 1658.72 (46.41 to 71.03)26.03 (15.12 to 36.94)
SecondaryASAS40 Response Rate in All Participants at Week 16

ASAS40 response was defined as relative improvement of at least 40% and absolute improvement of at least 2 units on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening at all in the remaining domain. The 4 main domains of the ASAS are: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of participants who achieved ASAS40 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of participants
ASAS40 Response Rate in All Participants at Week 16
Percentage of participantsSecukinumabPlacebo
ASAS40 Response Rate in All Participants at Week 1660.10 (48.46 to 71.75)24.78 (14.57 to 34.98)
SecondaryASAS 5/6 Response Rate at Week 16.

The ASAS 5/6 response was defined as an improvement of ≥20% in at least five of all six domains of the ASAS: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]); 5) spinal mobility represented by the BAS Disease Metrology Index (BASDMI) (scale ranged from 0 \[no limitation of movement\] to 10 \[very severe limitation of movement\]; and 6) C-reactive protein (acute phase reactant). The percentage of participants who achieved ASAS 5/6 response at Week 16 was assessed using a logistic regression model. Missing responses were imputed as non-responders. Discontinued participants were considered non-responders

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of participants
ASAS 5/6 Response Rate at Week 16.
Percentage of participantsSecukinumabPlacebo
ASAS 5/6 Response Rate at Week 16.61.97 (51.12 to 72.82)25.89 (16.13 to 35.64)
SecondaryChange From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 16

The BASDAI consisted of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which was used to answer 6 questions pertaining to the 5 major symptoms of AS: 1. Fatigue; 2. Spinal pain; 3. Joint pain / swelling; 4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments); 5. Morning stiffness duration; 6. Morning stiffness severity. BASDAI score was calculated as the mean of the questions 5 and 6. The resulting 0 to 10 score was added to the scores from questions 1-4. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score, where higher score indicated high disease activity. The change from baseline in BASDAI scores at Week 16 was assessed using Mixed-effects model repeated measures (MMRM). A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 16
Score on a scaleSecukinumabPlacebo
Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 16-3.70 ± 0.240-2.15 ± 0.237
SecondaryBASDAI 50 Rate at Week 16

The BASDAI consisted of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which was used to answer 6 questions pertaining to the 5 major symptoms of AS: 1. Fatigue; 2. Spinal pain; 3. Joint pain / swelling; 4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments); 5. Morning stiffness duration; 6. Morning stiffness severity. BASDAI score was calculated as the mean of the questions 5 and 6. The resulting 0 to 10 score was added to the scores from questions 1-4. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score, where higher score indicated high disease activity. BASDAI 50 was defined as an improvement of at least 50% in the BASDAI total score compared to baseline. The percentage of participants achieving BASDAI 50 at Week 16 was assessed using a logistic regression model. Discontinued participants and with missing responses were considered non-responders

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of participants
BASDAI 50 Rate at Week 16
Percentage of participantsSecukinumabPlacebo
BASDAI 50 Rate at Week 1664.04 (52.82 to 75.27)25.77 (15.68 to 35.85)
SecondaryChange From Baseline of High Sensitivity C-Reactive Protein (hsCRP) at Week 16

hsCRP was measured as a marker of inflammation from blood samples. The change from baseline in hsCRP at Week 16 was assessed using MMRM. It was expressed as a ratio of Week 16 to baseline values. Ratios less than 1.0 at Week 16 represented reduced hsCRP.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Ratio: Week 16 / Baseline
Change From Baseline of High Sensitivity C-Reactive Protein (hsCRP) at Week 16
Ratio: Week 16 / BaselineSecukinumabPlacebo
Change From Baseline of High Sensitivity C-Reactive Protein (hsCRP) at Week 160.38 ± 1.1370.74 ± 1.136
SecondaryChange From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16

The BASFI is a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The questions were chosen on the basis of predominant input from subjects with AS. The first eight questions consider activities related to functional anatomy. The final two questions assess the subjects' ability to cope with everyday life. A 0-10 scale (captured as a continuous VAS) is used to answer the questions. The BASFI score is the mean of the ten scales - a value between 0 and 10, with higher scores indicating a higher degree of functional limitation in patients. The change from baseline in BASFI at Week 16 was assessed. A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
Score on a ScaleSecukinumabPlacebo
Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16-2.04 ± 0.225-0.93 ± 0.222
SecondaryChange From Baseline in Sacroiliac Joint (SIJ) Edema Score on Magentic Resonance Imaging (MRI) at Week 16

The MRI assessment of the total edema score of the Sacroiliac Joint (SIJ) measured the degree of edema or fluid accumulation in the joint. The score ranged from 0 to 24, with higher scores indicating more severe inflammation. The change from baseline in inflammation, as measured by the SI joint total edema score at Week 16, was evaluated using an ANCOVA model. Any missing data was imputed using multiple imputation prior to running the ANCOVA analysis.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Sacroiliac Joint (SIJ) Edema Score on Magentic Resonance Imaging (MRI) at Week 16
Score on a ScaleSecukinumabPlacebo
Change From Baseline in Sacroiliac Joint (SIJ) Edema Score on Magentic Resonance Imaging (MRI) at Week 16-3.09 ± 0.34-0.84 ± 0.35
SecondaryASAS20 Response Rate at Week 16

ASAS20 response was defined as relative improvement of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening of ≥20% and ≥1 unit at all in the remaining domain. The 4 main domains of ASAS are 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]) The percentage of participants who achieved ASAS20 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of participants
ASAS20 Response Rate at Week 16
Percentage of participantsSecukinumabPlacebo
ASAS20 Response Rate at Week 1678.10 (68.29 to 87.91)47.60 (35.82 to 59.39)
SecondaryChange From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS) at Week 16

SF-36 was an instrument used to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consisted of eight subscales (domains) that could be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Each domain score ranged from 0 to 100, with higher scores indicating a higher level of functioning. The Physical Component Summary (PCS) was an overall summary score calculated from the 8 domains. It was a norm-based score with a mean of 50 and a standard deviation of 10. Higher scores indicated a higher level of functioning. The change from baseline in PCS at Week 16 was evaluated using MMRM. A positive change from baseline indicated an improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS) at Week 16
Score on a ScaleSecukinumabPlacebo
Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS) at Week 169.35 ± 0.7724.34 ± 0.753
SecondaryChange From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16

The ASQoL was a self-administered questionnaire designed to assess health-related quality of life (HRQoL) in participants with ankylosing spondylitis. The ASQoL contained 18 items with a dichotomous yes/no response option. A single point was assigned for each "yes" response and no points for each "no" response resulting in overall scores that ranged from 0 (least severity) to 18 (highest severity). As such, a lower score indicated a better quality of life. Items included an assessment of mobility/energy, self-care, and mood/emotion. The change from baseline in ASQoL at Week 16 was assessed using MMRM. A negative change from baseline indicated an improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16
Score on a scaleSecukinumabPlacebo
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16-4.90 ± 0.455-3.07 ± 0.447
SecondaryASAS Partial Remission Rate at Week 16

The ASAS partial remission criteria were defined as a value not above 2 units (on a scale of 10) in each of the 4 main ASAS domains: 1. Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2. Back Pain (assessed on a scale of 0 \[no pain\] to 10 \[severe pain\]); 3. Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4. Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of participants who achieved ASAS partial remission response at Week 16 was assessed using a logistic regression model. Missing responses were imputed as non-responders. Discontinued participants were considered non-responders.

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of participants
ASAS Partial Remission Rate at Week 16
Percentage of participantsSecukinumabPlacebo
ASAS Partial Remission Rate at Week 1630.83 (19.92 to 41.73)14.52 (6.23 to 22.80)

Adverse events

Collected over From start of treatment to end of study, assessed up to approximately 65 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 150 mg0/135 (0%)4/135 (3%)103/135 (76.3%)
Secukinumab 300 mg0/29 (0%)2/29 (6.9%)22/29 (75.9%)
Any Secukinumab0/135 (0%)6/135 (4.4%)114/135 (84.4%)
Placebo0/69 (0%)1/69 (1.4%)52/69 (75.4%)
Most frequent serious events
Most frequent serious events
EventSecukinumab 150 mgSecukinumab 300 mgAny SecukinumabPlacebo
ParonychiaInfections and infestations0/1351/291/1350/69
TonsillitisInfections and infestations0/1351/291/1350/69
Anal fistulaGastrointestinal disorders0/1350/290/1351/69
Gastritis erosiveGastrointestinal disorders1/1350/291/1350/69
Rib fractureInjury, poisoning and procedural complications1/1350/291/1350/69
Neuroendocrine tumour of the rectumNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1350/291/1350/69
Plasma cell mastitisReproductive system and breast disorders1/1350/291/1350/69
Most frequent other events
Showing 10 of 25
Most frequent other events
EventSecukinumab 150 mgSecukinumab 300 mgAny SecukinumabPlacebo
Upper respiratory tract infectionInfections and infestations43/1357/2949/13522/69
HyperuricaemiaMetabolism and nutrition disorders26/1354/2928/13510/69
COVID-19Infections and infestations23/1354/2927/1357/69
HyperlipidaemiaMetabolism and nutrition disorders23/1350/2923/13510/69
Back painMusculoskeletal and connective tissue disorders4/1350/294/13510/69
ArthralgiaMusculoskeletal and connective tissue disorders5/1354/299/1354/69
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders14/1351/2915/1350/69
Low density lipoprotein increasedInvestigations14/1351/2914/1355/69
PharyngitisInfections and infestations3/1353/295/1351/69
Suspected COVID-19Infections and infestations11/1351/2912/1352/69

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SecukinumabPlaceboTotal
Mean29.4 ± 7.8329.4 ± 7.4429.4 ± 7.61
Sex: Female, Male
Sex: Female, Male(Participants)SecukinumabPlaceboTotal
Female231740
Male455297
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SecukinumabPlaceboTotal
Asian6869137
TNF-alpha inhibitors exposure
TNF-alpha inhibitors exposure(Participants)SecukinumabPlaceboTotal
TNF alpha-inhibitor-naive6162123
Prior exposure to a TNF-alpha inhibitor7714
08

Study locations

29 sites
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Hefei, Anhui 230601, China
  • Novartis Investigative Site
    Beijing, Beijing Municipality 100044, China
  • Novartis Investigative Site
    Xiamen, Fujian 361001, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510030, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Shantou, Guangdong 515000, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518020, China
  • Novartis Investigative Site
    Harbin, Heilongjiang 150000, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Changsha, Hunan 410011, China
  • Novartis Investigative Site
    Baotou, Inner Mongolia 014010, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210008, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210009, China
  • Novartis Investigative Site
    Yangzhou, Jiangsu 225001, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Pingxiang, Jiangxi 337000, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Linyi, Shandong 276000, China
  • Novartis Investigative Site
    Ürümqi, Xinjiang 830001, China
  • Novartis Investigative Site
    Kunming, Yunnan 650000, China
  • Novartis Investigative Site
    Ningbo, Zhejiang 315016, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
  • Novartis Investigative Site
    Beijing, 100000, China
  • Novartis Investigative Site
    Beijing, 100050, China
  • Novartis Investigative Site
    Bengbu, 233004, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Shanghai, 200050, China
  • Novartis Investigative Site
    Tianjin, 300052, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Apr 2024, 32 months.

Results were first posted in Jan 2026, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 1, 2021
StartActual
Jul 21, 2021
Primary completionActual
Apr 3, 2024
CompletionActual
Feb 14, 2025
Results first posted
Jan 30, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04732117
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
Jul 21, 2021
Primary completion
Apr 3, 2024
Completion
Feb 14, 2025
Results posted
Jan 30, 2026
Last update
Apr 9, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion